Objective To observe the short-term potassium-lowering effect and adverse reactions of sodi-um zirconium cyclosilicate dispersion in patients with hyperkalemia.Methods The clinical data of 50 inpa-tients with hyperkalemia who received sodium zirconium cyclosilicate dispersion at Xining City First People's Hospital from November 2020 to March 2022 were collected and retrospectively analyzed for the potassium-lowering effects after 2 hours and 8 hours post-medication as well as any adverse drug reactions.Results Blood potassium levels after 2 hours and 8 hours post-medication were significantly lower than those before medication(t=10.034 and 14.654,P＜0.001),while there were no significant differences in blood sodium,cal-cium,magnesium,CO2CP,ALT,and AST levels before and after medication(P＞0.05).Scatter plot analysis showed a linear positive correlation between the degree of decrease in blood potassium at 2 hours and 8 hours post-medication and the pre-medication blood potassium levels(r-0.298 and 0.579,P=0.038 and＜0.001).There was no statistically significant difference in the degree of potassium reduction between the group with GFR ≤ 15ml/min and the group with＞15 ml/min at both 2 hours and 8 hours post-medication(t=-1.452 and 1.594,P=0.153 and 0.118).During treatment,two patients experienced mild nausea after taking the drug.Conclusion Sodium zirconium cylcosilicate dispersion can safely and effectively reduce blood potassium lev-els within 2-8 hours in patients with hyperkalemia without severe adverse reactions.
万方数据
维普
